Assessment of Early-detection Based on Liquid Biopsy in Lymphoid Malignancies
NCT ID: NCT05275036
Last Updated: 2022-04-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
493 participants
OBSERVATIONAL
2022-05-31
2025-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AssesSment of Early deteCtion basEd oN liquiD Biopsy in Intracranial Tumors
NCT05679089
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in GASTRIC Cancer, ASCEND-Gastric
NCT05224596
Clinical Application of Liquid Biopsy for Precise Diagnosis and Prognosis in Lymphoma
NCT04062877
Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma
NCT05693012
Use of Circulating Exosomal LncRNA-GC1 to Monitor Gastric Cancer
NCT05397548
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cancer Arm
Participants with new diagnosis of lymphoid malignancies, from whom blood samples will be collected.
early detection test
Blood collection and early detection testing
Benign Arm
Participants with new diagnosis of benign lymphoid diseases, from whom blood samples will be collected.
early detection test
Blood collection and early detection testing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
early detection test
Blood collection and early detection testing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to provide a written informed consent.
* No prior cancer treatment (local or systematic) prior to blood draw.
* High suspicious or pathologically confirmed lymphoid malignancies within 42 days prior to blood draw.
* No prior radical treatment of the benign diseases prior to study blood draw
* Pathologically confirmed diagnosis of lymphoid benign diseases within 90 days prior to blood draw.
Exclusion Criteria
* During pregnancy or lactation.
* Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.
* Recipient of blood transfusion within 7 days prior to blood draw.
* Recipient of anti-tumor drugs to treat non-cancer diseases within 30 days prior to blood draw, such as rheumatic drugs (methotrexate, cyclophosphamide, or azathioprine), or endocrine drugs (tamoxifen).
* With other known malignant tumors or multiple primary tumors.
* Lymphoid malignancies unable to comfirmed by imaging tests or pathological cancer diagnosis within 42 days after the blood draw.
* With other known malignant tumors or comfirmed lymphoid malignancies.
* Lymphoid benign diseases unable to comfirmed by imaging tests or pathological cancer diagnosis within 42 days after the blood draw.
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangzhou Burning Rock Dx Co., Ltd.
INDUSTRY
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Huiqiang Huang
chief physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Huiqiang Huang, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Department of Medical Oncology, Sun Yat-sen University Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SunYat-sen university cancer center
Guangzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yan Gao
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BRCD2022003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.